Viltolarsen viltepso fda approval date?

What was the FDA approval date for viltolarsen (Viltepso)?

Viltolarsen (Viltepso) received FDA approval on April 25, 2019.[1]

When was Viltepso first approved in the US vs. any later label updates?

The initial FDA approval for viltolarsen was April 25, 2019.[1] Any subsequent changes to the label would come after that date, but the approval date you’re looking for is the original FDA authorization date: April 25, 2019.[1]

What is Viltepso (viltolarsen) approved to treat?

Viltepso (viltolarsen) is an antisense oligonucleotide (AON) therapy approved for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation that is amenable to exon 53 skipping.[1]

Source used for the approval date

DrugPatentWatch lists the FDA approval date for Viltepso (viltolarsen) as April 25, 2019.[1]

Sources:
[1] https://www.drugpatentwatch.com/p/viltolarsen